$58.38 5.0 9.3%
Last Trade - 4:06pm
| Market Cap | ÂŁ2.27bn |
| Enterprise Value | ÂŁ2.02bn |
| Revenue | ÂŁ82.7m |
| Position in Universe | 1704th / 6566 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 38.2 | 49.5 | 65.1 | 72.0 | 92.0 | 120.4 | 114.9 | 152.3 | +25.8% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | August 15, 2006 |
| Public Since | October 30, 2013 |
| No. of Shareholders: | n/a |
| No. of Employees: | 354 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 57,897,321 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 6000 Shoreline Ct Ste 300, SOUTH SAN FRANCISCO, 94080-7606, United States |
| Web | https://www.veracyte.com/ |
| Phone | +1 650 2436300 |
| Contact | Tracy Morris (IR Contact Officer) |
| Auditors | Ernst & Young LLP |
As of 4:06pm, shares in Veracyte Inc are trading at $58.38, giving the company a market capitalisation of ÂŁ2.27bn. This share price information is delayed by 15 minutes.
Shares in Veracyte Inc are currently trading at $58.38 and the price has moved by 77.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Veracyte Inc price has moved by 56.08% over the past year.
Of the analysts with advisory recommendations for Veracyte Inc, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Veracyte Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Veracyte Inc is scheduled to issue upcoming financial results on the following dates:
Veracyte Inc does not currently pay a dividend.
Veracyte Inc does not currently pay a dividend.
Veracyte Inc does not currently pay a dividend.
To buy shares in Veracyte Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Veracyte Inc are currently trading at $58.38, giving the company a market capitalisation of ÂŁ2.27bn.
Here are the trading details for Veracyte Inc:
Based on an overall assessment of its quality, value and momentum, Veracyte Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Veracyte Inc are currently priced at $58.38. At that level they are trading at 13.48% premium to the analyst consensus target price of 0.00.
Analysts covering Veracyte Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.626 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veracyte Inc. Over the past six months, the relative strength of its shares against the market has been 47.19%. At the current price of $58.38, shares in Veracyte Inc are trading at 50.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Veracyte Inc.
Veracyte Inc's management team is headed by:
Here are the top five shareholders of Veracyte Inc based on the size of their shareholding:
